Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

OBJECTIVE: To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12‐month phase III trial in patients with tophaceous gout. METHODS: Patients with serum urate (UA) ≥8.0 mg/dl (≥6.0 mg/dl with urate‐lowering therapy) and ≥1 measurable target tophus were given febuxos...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalbeth, Nicola, Jones, Graeme, Terkeltaub, Robert, Khanna, Dinesh, Kopicko, Jeff, Bhakta, Nihar, Adler, Scott, Fung, Maple, Storgard, Chris, Baumgartner, Scott, Perez‐Ruiz, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Gout
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601200/
https://www.ncbi.nlm.nih.gov/pubmed/28597604
http://dx.doi.org/10.1002/art.40159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601200/
https://www.ncbi.nlm.nih.gov/pubmed/28597604
http://dx.doi.org/10.1002/art.40159

Ejemplares similares